A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia Treated With Nilotinib
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single arm, phase II study to assess the effect of nilotinib reduced
to half the standard dose for 12 months on treatment-free remission in patients with Chronic
Myeloid Leukemia - Chronic Phase (CML-CP) treated with first-line nilotinib who reached a
sustained deep molecular response before entering the study.